ALLIANCES AND COLLABORATIONS (Tables)

6 Months Ended

Jun. 30, 2012

Sanofi [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012			2011	2012			2011
Territory covering the Americas and Australia:
	Net sales	$	778	$	2,045	$	2,595	$	4,023
	Royalty expense		141		397		508		755
	Noncontrolling interest – pre-tax		249		601		854		1,174
	Profit distributions to Sanofi		(449)		(702)		(1,058)		(1,301)
Territory covering Europe and Asia:
	Equity in net income of affiliates		(58)		(65)		(118)		(151)
	Profit distributions to BMS		62		67		129		127
Other:
	Net sales in Europe comarketing countries and other		80		71		163		145
	Amortization (income)/expense – irbesartan license fee		(8)		(8)		(16)		(16)
	Supply activities and development and opt-out royalty (income)/expense		(39)		1		(45)		15
						June 30,		December 31,
Dollars in Millions						2012		2011
Investment in affiliates – territory covering Europe and Asia						$	26	$	37
Deferred income – irbesartan license fee							13		29

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Alliances and Collaborations Statement [Line Items]

Equity Method Investments Disclosure [Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2012		2011		2012		2011
Net sales	$	319	$	382	$	638	$	761
Gross profit		132		172		270		340
Net income		120		142		242		282

Otsuka [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012		2011		2012		2011
Abilify*	net sales, including amortization of extension payment	$	711	$	706	$	1,332	$	1,330
Oncology Products collaboration fee expense			35		37		67		70
Royalty expense			20		18		37		35
Commercialization expense reimbursement to/(from) Otsuka			(19)		(11)		(32)		(22)
Amortization (income)/expense – extension payment			17		17		33		33
Amortization (income)/expense – upfront, milestone and other
licensing payments			2		2		4		4
						June 30,		December 31,
Dollars in Millions						2012		2011
Other assets - extension payment						$	186	$	219
Other intangible assets - upfront, milestone and other licensing payments							1		5

Lilly [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012		2011		2012		2011
Net sales		$	179	$	173	$	358	$	338
Distribution fees and royalty expense			75		71		149		140
Research and development expense reimbursement to Lilly – necitumumab			7		4		8		6
Amortization (income)/expense – upfront, milestone and other
	licensing payments		9		9		19		19
Commercialization expense reimbursements to/(from) Lilly			(6)		(2)		(10)		(3)
Japan commercialization profit sharing (income)/expense			(13)		(6)		(19)		(15)
						June 30,		December 31,
Dollars in Millions						2012		2011
Other intangible assets – upfront, milestone and other licensing payments						$	230	$	249

Gilead [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2012		2011		2012		2011
Net sales	$	323	$	298	$	645	$	569
Equity in net loss of affiliates		4		3		8		8

AstraZeneca [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012		2011		2012		2011
Net sales		$	172	$	112	$	333	$	193
Profit sharing expense			77		52		150		90
Commercialization expense reimbursements to/(from) AstraZeneca			(7)		(10)		(19)		(19)
Research and development expense reimbursements to/(from) AstraZeneca			6		15		10		29
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(11)		(10)		(21)		(18)
						June 30,		December 31,
Dollars in Millions						2012		2011
Deferred income – upfront, milestone and other licensing payments
	Saxagliptin					$	217	$	230
	Dapagliflozin						134		142

Pfizer [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2012		2011		2012		2011
Net sales		$	1	$	-	$	1	$	-
Commercialization expense reimbursement to/(from) Pfizer			(3)		(2)		(8)		(3)
Research and development reimbursements to/(from) Pfizer			9		(27)		11		(56)
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(9)		(8)		(19)		(16)
						June 30,		December 31,
Dollars in Millions						2012		2011
Deferred income – upfront, milestone and other licensing payments						$	415	$	434